<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077139</url>
  </required_header>
  <id_info>
    <org_study_id>CRT in PH</org_study_id>
    <nct_id>NCT03077139</nct_id>
  </id_info>
  <brief_title>Cardiac Resynchronization Therapy in Pulmonary Hypertension</brief_title>
  <acronym>CRT in PH</acronym>
  <official_title>Cardiac Resynchronization Therapy in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Daniel P Morin, MD MPH FHRS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine whether patients with advanced pulmonary
      hypertension when treated with cardiac resynchronization therapy improve hemodynamically
      and/or receive clinical benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine whether stimulating earlier activation of the failing right
      ventricle in pulmonary hypertension reduces the effects of interventricular dependence in
      human subjects, thereby improving overall cardiac function and symptoms in patients with
      pulmonary hypertension and right ventricle failure with NYHA Class 3-4 symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2012</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">March 23, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>15% increase in cardiac output at the optimal VV interval over baseline cardiac output</measure>
    <time_frame>the procedure</time_frame>
    <description>Primary Outcome</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Arms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pacing wires used to stimulate ventricles in a synchronous matter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy (CRT)</intervention_name>
    <description>A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.</description>
    <arm_group_label>Arms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pulmonary hypertension, defined as pulmonary artery systolic pressure greater than 40
             mm Hg by transthoracic echocardiogram or right heart catheterization

          -  LVEF ≥ 50%

          -  Baseline 6MWT distant &lt;400 meters

          -  Baseline NYHA Functional class ≥ III

        Exclusion Criteria:

          -  LVEF &lt; 50%

          -  6MWT duration &gt; 400 meters

          -  NYHA Functional class &lt; III

          -  Left bundle branch block

          -  Non-sinus rhythm

          -  Severe aortic stenosis (Aortic valve area &lt; 1 cm2)

          -  Severe mitral regurgitation

          -  Acute cardiac failure

          -  Dependency on intravenous inotropies

          -  Severe obstructive pulmonary disease

          -  Hypertrophic obstructive cardiomyopathy

          -  Amyloidosis

          -  Dependence on pacing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Morin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Electrophysiologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Dr. Daniel P Morin, MD MPH FHRS</investigator_full_name>
    <investigator_title>Cardiac Electrophysiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

